Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity

References

• Atigari OV, Healy D. 2013. Sustained antidepressant response to ketamine. BMJ Case Rep. 2013:bcr2013200370.
   PubMedGoogle Scholar
• Baczkowski BM, van Zutphen L, Siep N, Jacob GA, Domes G, Maier S, Sprenger A, Senft A, Willenborg B, Tüscher O, et al. 2017. Deficient amygdala-prefrontal intrinsic connectivity after effortful emotion regulation in borderline personality disorder. Eur Arch Psychiatry Clin Neurosci. 267(6):551–565. doi: 10.1007/s00406-016-0760-z.
   PubMed Web of Science ®Google Scholar
• Belli H, Ural C, Akbudak M. 2012. Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment. J Clin Med Res. 4(5):301–308. doi: 10.4021/jocmr1042w.
   PubMedGoogle Scholar
• Carter TD, Mundo E, Parikh SV, Kennedy JL. 2003. Early age at onset as a risk factor for poor outcome for bipolar disorder. J Psychiatr Res. 37(4):297–303. doi: 10.1016/s0022-3956(03)00052-9.
   PubMed Web of Science ®Google Scholar
• Coccaro EF, Lee R, Vezina P. 2013. Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects. J Psychiatr Res. 47(9):1247–1253. doi: 10.1016/j.jpsychires.2013.05.001.
   PubMed Web of Science ®Google Scholar
• Cusin C, Hilton GQ, Nierenberg AA, Fava M. 2012. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 169(8):868–869. doi: 10.1176/appi.ajp.2012.12020219.
   PubMed Web of Science ®Google Scholar
• Domany Y, Shelton RC, McCullumsmith CB. 2020. Ketamine for acute suicidal ideation. an emergency department intervention: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety. 37(3):224–233. doi: 10.1002/da.22975.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Crotty K, Kennedy S, Edlund MJ, Ali R, Siddiqui M, Fortman R, Wines R, Persad E, Viswanathan M. 2021. Pharmacological treatments for borderline personality disorder: a systematic review and meta-analysis. CNS Drugs. 35(10):1053–1067. doi: 10.1007/s40263-021-00855-4.
   PubMed Web of Science ®Google Scholar
• Hancock-Johnson E, Griffiths C, Picchioni M. 2017. A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs. 31(5):345–356. doi: 10.1007/s40263-017-0425-0.
   PubMed Web of Science ®Google Scholar
• Jimenez-Trevino L, Gonzalez-Blanco L, Alvarez-Vazquez C, Rodriguez-Revuelta J, Saiz Martinez PA. 2020. Glutamine and new pharmacological targets to treat suicidal ideation. Curr Top Behav Neurosci. 46:179–196.
   PubMedGoogle Scholar
• Kantrowitz JT, Halberstam B, Gangwisch J. 2015. Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry. 76(6):737–738. doi: 10.4088/JCP.14l09527.
   PubMed Web of Science ®Google Scholar
• Kasper S, Cubała WJ, Fagiolini A, Ramos-Quiroga JA, Souery D, Young AH. 2021. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance. World J Biol Psychiatry. 22(6):468–482. doi: 10.1080/15622975.2020.1836399.
   PubMed Web of Science ®Google Scholar
• Lara DR, Bisol LW, Munari LR. 2013. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 16(9):2111–2117. doi: 10.1017/S1461145713000485.
   PubMed Web of Science ®Google Scholar
• Lengvenyte A, Olié E, Courtet P. 2019. Suicide has many faces, So does ketamine: a narrative review on ketamine’s antisuicidal actions. Curr Psychiatry Rep. 21(12):132. doi: 10.1007/s11920-019-1108-y.
   PubMed Web of Science ®Google Scholar
• Lynch TR, Trost WT, Salsman N, Linehan MM. 2007. Dialectical behavior therapy for borderline personality disorder. Annu Rev Clin Psychol. 3:181–205. doi: 10.1146/annurev.clinpsy.2.022305.095229.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. 2007. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 61(9):1039–1048. doi: 10.1016/j.biopsych.2006.08.008.
   PubMed Web of Science ®Google Scholar
• Mechler K, Häge A, Schweinfurth N, Glennon JC, Dijkhuizen RM, Murphy D, Durston S, Williams S, K Buitelaar J, Banaschewski T, et al. 2018. Glutamatergic agents in the treatment of compulsivity and impulsivity in child and adolescent psychiatry: a systematic review of the literature. Z Kinder Jugendpsychiatr Psychother. 46(3):246–263. doi: 10.1024/1422-4917/a000546.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs I, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, et al. 2003. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry. 60(1):82–91. doi: 10.1001/archpsyc.60.1.82.
   PubMed Web of Science ®Google Scholar
• Miller DD. 2000. Review and management of clozapine side effects. J Clin Psychiatry. 61(8):14–17. discussion 18-9.
   PubMedGoogle Scholar
• Nandan NK, Soni PK, Parsaik A, Hashmi A. 2022. “Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality. Cureus. 4(4):e24632.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). 2009. Borderline personality disorder: recognition and management. Clinical guideline. Published: 28 January 2009. https://www.nice.org.uk/guidance/cg78.
   Google Scholar
• Orhurhu VJ, Vashisht R, Claus LE, Cohen SP. 2023. Ketamine toxicity. In: StatPearls. Treasure Island, FL: StatPearls Publishing.
   Google Scholar
• Papolos DF, Teicher MH, Faedda GL, Murphy P, Mattis S. 2013. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. J Affect Disord. 147(1–3):431–436. doi: 10.1016/j.jad.2012.08.040.
   PubMed Web of Science ®Google Scholar
• Patel RS, Manikkara G, Chopra A. 2019. Bipolar disorder and comorbid borderline personality disorder: patient characteristics and outcomes in US hospitals. Medicina. 55(1):13. doi: 10.3390/medicina55010013.
   PubMed Web of Science ®Google Scholar
• Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye O, Batten LA, Blier P. 2019. Single, repeated, and maintenance ketamine infusions for Treatment-Resistant depression: a randomized controlled trial. Am J Psychiatry. 176(5):401–409. doi: 10.1176/appi.ajp.2018.18070834.
   PubMed Web of Science ®Google Scholar
• Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ. 2014. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 31(4):335–343. doi: 10.1002/da.22253.
   PubMed Web of Science ®Google Scholar
• Rubio G, Martinez-Gras I, Manzanares J. 2009. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol. 29(6):584–589. doi: 10.1097/JCP.0b013e3181bfdb79.
   PubMed Web of Science ®Google Scholar
• Saunders KEA, Jones T, Perry A, Di Florio A, Craddock N, Jones I, Gordon-Smith K, Jones L. 2021. The influence of borderline personality traits on clinical outcomes in bipolar disorder. Bipolar Disord. 23(4):368–375.
   PubMed Web of Science ®Google Scholar
• Stoffers-Winterling J, Storebø OJ, Lieb K. 2020. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep. 22(8):37. doi: 10.1007/s11920-020-01164-1.
   PubMed Web of Science ®Google Scholar
• Thomas N, Gurvich C, Kulkarni J. 2019. Borderline personality disorder, trauma, and the hypothalamus-pituitary-adrenal axis. Neuropsychiatr Dis Treat. 15:2601–2612. doi: 10.2147/NDT.S198804.
   PubMed Web of Science ®Google Scholar
• Vanicek T, Unterholzner J, Lanzenberger R, Naderi-Heiden A, Kasper S, Praschak-Rieder N. 2022. Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World J Biol Psychiatry. 23(9):715–718. doi: 10.1080/15622975.2022.2031287.
   PubMed Web of Science ®Google Scholar
• Walsh Z, Mollaahmetoglu OM, Rootman J, Golsof S, Keeler J, Marsh B, Nutt DJ, Morgan CJA. 2021. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 8(1):e19. Erratum in: BJPsych Open. 2022;8(1):e29. doi: 10.1192/bjo.2021.1061.
   PubMed Web of Science ®Google Scholar
• Wilkowska A, Wiglusz MS, Cubała WJ. 2019. Clozapine in treatment-resistant bipolar disorder with suicidality. Three Case Rep. 10:520.
   Google Scholar
• Wilkowska A, Włodarczyk A, Gałuszko-Węgielnik M, Wiglusz MS, Cubała WJ. 2021. Intravenous ketamine infusions in treatment-resistant bipolar depression: an open-label naturalistic observational study. Neuropsychiatr Dis Treat. 17(17):2637–2646. doi: 10.2147/NDT.S325000.
   PubMedGoogle Scholar
• Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, Cipriani A, Hawton K. 2020. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust NZ J Psychiatry. 54(1):29–45. doi: 10.1177/0004867419883341.
   PubMed Web of Science ®Google Scholar
• Włodarczyk A, Cubała WJ, Gałuszko-Węgielnik M, Szarmach J. 2021. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. Medicine. 100(29):e26769. doi: 10.1097/MD.0000000000026769.
   PubMed Web of Science ®Google Scholar
• Yavi M, Lee H, Henter ID, Park LT, Zarate CA. Jr. 2022. Ketamine treatment for depression: a review. Discov Ment Health. 2(1):9. doi: 10.1007/s44192-022-00012-3.
   PubMedGoogle Scholar
• Zarate CA, Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. 2012. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 71(11):939–946. doi: 10.1016/j.biopsych.2011.12.010.
   PubMed Web of Science ®Google Scholar